The UK’s Horizon trial will test a vaccine against the Epstein-Barr virus (EBV), linked to multiple sclerosis, aiming to train the immune system and explore a potential new treatment for MS.
The projects will happen in 14 Member States and the United Kingdom, with 36 million in funding to get COVID-19 plasma to patients - boosting their immune response to the virus.
The approval of the Moderna COVID vaccine in the UK comes 2 days after European medical regulators, but not a moment too soon - the death toll continues to climb, standing at 78,508 currently.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Yesterday, at 6:45am in the US, the Pfizer vaccine was revealed to be over 90% effective - so when will the successful drug be available for the UK to use?
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, China charts how to deal with dementia during the COVID-19 pandemic, starting with a helpful global and regional overview.
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, explores if digital twins are game-changers in clinical research and clinical care.
